Application of carnosic acid in preparation of medicine for treating or improving metabolism-related fatty liver disease
By inhibiting the antagonist effect of PPARα and PPARγ, saccharic acid inhibits fatty acid uptake and promotes triglyceride secretion in metabolic-related fatty liver disease, solving the shortcomings of existing treatment methods on metabolism-related fatty liver disease, significantly improving the liver and metabolism Function.
Patent Information
- Application Number
- CN202410976087.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
Existing methods for treating metabolic-related fatty liver diseases have not been approved by the FDA or EMA, and existing drugs have limited regulatory effects on liver fatty acid uptake and triglyceride secretion mechanisms.
As an antagonist of PPARα and PPARγ, sage acid inhibits the expression of genes and proteins related to fatty acid uptake in liver cells, promotes the secretion of triglycerides, and thus improves metabolic-related fatty liver disease.
By inhibiting the transcriptional activities of PPARα and PPARγ, the expression of fatty acid uptake genes and proteins is reduced, triglyceride secretion is promoted, and the fatty liver and metabolic disorders induced by high-fat diets are significantly improved, the liver lipid deposition and body weight are reduced, and the sugar metabolism function is improved.
Smart Images

Figure CN118924723A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of biomedical technology, and in particular, to the use of carnosic acid in preparing a medicament for treating or improving metabolism-related fatty liver disease. Background Art
[0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized by excessive liver fat accumulation and greater than 5% fat storage in hepatocytes in patients with no history of alcoholism or other secondary causes of hepatic steatosis. It is usually accompanied by obesity, impaired glucose tolerance, insulin resistance, and dyslipidemia. Currently, the treatment of NAFLD is mainly reversed by drug intervention and changes in the patient's lifestyle. However, there is still no FDA or EMA-approved treatment for NAFLD. In 2020, NAFLD was renamed "metabolic-associated fatty liver disease" by consensus of members of an international expert group.
[0003] The diagnostic criteria for metabolic related fatty liver disease (MAFLD) are that the patient is diagnosed with fatty liver and is accompanied by one of the three conditions of obesity, type 2 diabetes or metabolic dysfunction. At the same time, the focus of clinical diagnosis and treatment of NAFLD has gradually shifted from emphasizing liver lesions and liver disease-related results to the prevention and treatment of obesity, type 2 diabetes and metabolic dysfunction-related diseases. Although the FDA has not yet approved drugs for the treatment of NAFLD, drugs that have been approved for the treatment of comorbidities and have potential benefits for NAFLD can be considered in the presence of comorbidities. For example, antidiabetic drugs PPARγ agonists, GLP-1 agonists and SGLT2 inhibitors have been reported to improve fatty liver disease. GW9662 is a selective PPAR antagonist that acts on PPARγ and PPARα, but its inhibitory effect on PPARα is 1 / 10 of that on PPARγ.
[0004] Carnosic acid (CA) is a diterpenoid compound isolated from the leaves of the plant Rosmarinus officinalis. Related studies have shown that CA has the effect of improving fatty liver, mainly by inhibiting the activation of PI3K / AKT, NLRP3 / NF-кB and SREBP1c signaling pathways. However, the effect of carnosic acid on the treatment of metabolic-related fatty liver disease has not been reported. Therefore, it is of great significance to study the effect of carnosic acid on the treatment or improvement of metabolic-related fatty liver disease and to develop drugs for the treatment or improvement of metabolic-related fatty liver disease. Summary of the invention
[0005] The purpose of the present disclosure is to provide a method for preparing a drug for treating or improving metabolic-related fatty liver disease. The inventors of the present disclosure surprisingly found that carnosic acid can be used as an antagonist of PPARα subtype and PPARγ subtype, and can also inhibit the expression of fatty acid uptake-related genes and proteins in liver cells, and promote the secretion of triglycerides in liver cells, providing a new strategy for treating or improving metabolic-related fatty liver disease.
[0006] In order to achieve the above-mentioned object, the present disclosure provides, in a first aspect, the use of carnosic acid as a peroxisome proliferator-activated receptor antagonist.
[0007] Optionally, the carnosic acid acts as an antagonist of the PPARα subtype and / or PPARγ subtype of peroxisome proliferator-activated receptors.
[0008] A second aspect of the present disclosure provides use of carnosic acid in the preparation of a medicament for treating or improving metabolism-related fatty liver disease.
[0009] Optionally, the drug treats or improves metabolism-related fatty liver disease in at least one of the following ways: (1) inhibiting the transcription of peroxisome proliferator-activated receptors; (2) inhibiting the expression of fatty acid uptake-related genes in liver cells; (3) inhibiting the expression of fatty acid uptake-related proteins in liver cells and / or small intestinal cells; (4) promoting the secretion of triglycerides in liver cells.
[0010] Optionally, the peroxisome proliferator-activated receptor is a PPARα subtype and / or a PPARγ subtype of a peroxisome proliferator-activated receptor; the fatty acid uptake-related gene is selected from one or more of FATP1, FABP1, FABP3 and CD36; the fatty acid uptake-related protein is selected from one or more of FATP1, FABP1 and CD36.
[0011] Optionally, the metabolism-related fatty liver disease is based on fatty liver disease and is accompanied by at least one selected from obesity, type 2 diabetes and metabolic dysfunction.
[0012] Optionally, the metabolic dysfunction is selected from abnormalities in at least two metabolic risk factors among central obesity, hypertension, hyperlipidemia, prediabetes and insulin resistance.
[0013] Optionally, the metabolism-related fatty liver disease is fatty liver disease accompanied by prediabetes.
[0014] Optionally, the drug further comprises a pharmaceutically acceptable excipient.
[0015] Optionally, the pharmaceutically acceptable excipient is selected from one or more of an excipient, a filler, a binder, a diluent and a disintegrant.
[0016] Through the above technical scheme, the present disclosure provides the use of carnosic acid in the preparation of a drug for treating or improving metabolism-related fatty liver disease. Carnosic acid can be used as an antagonist of PPARα subtype and PPARγ subtype, and can also inhibit the expression of fatty acid uptake-related genes (FATP1, FABP1, FABP3, CD36) in liver cells, inhibit the expression of fatty acid-related proteins CD36 and FATP1 in liver cells, and promote the secretion of triglycerides in liver cells, inhibit the expression of fatty acid uptake-related proteins CD36 and FABP1 in small intestinal cells, thereby achieving the effect of treating and / or improving metabolism-related fatty liver disease, providing a new strategy for treating or improving metabolism-related fatty liver disease.
[0017] Other features and advantages of the present disclosure will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The accompanying drawings are used to provide a further understanding of the present disclosure and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present disclosure but do not constitute a limitation of the present disclosure. In the accompanying drawings:
[0019] Figure 1 This is an analysis diagram of the affinity between PPARγ and CA.
[0020] Figure 2 This is the experimental result of the effect of CA on the binding of PPARγ to SA-SRC1 / GST-NCOR2.
[0021] Figure 3 This is the experimental result of the effect of CA on the binding of PPARα to SA-SRC1.
[0022] Figure 4 The effect of CA and GW9662 on PPARγ transcriptional activity.
[0023] Figure 5 The effect of CA on the liver-to-body ratio of fatty liver induced by high-fat diet.
[0024] Figure 6 These are the ultrasound results of small animals with CA intervention in fatty liver induced by high-fat diet.
[0025] Figure 7 These are the results of liver and kidney ultrasound ratio in patients with fatty liver induced by high-fat diet after CA intervention.
[0026] Figure 8 The effect of CA on liver damage in high-fat diet-induced fatty liver.
[0027] Fig. 9 is the effect of CA on high-fat diet-induced hepatic lipid deposition.
[0028] Fig.10 The effect of CA on body weight and food intake induced by a high-fat diet.
[0029] Fig.11 The effect of CA on glucose metabolism induced by high-fat diet feeding.
[0030] Fig.12 is the effect of CA on fatty acid uptake capacity of mice fed a high-fat diet.
[0031] Fig.13 is the effect of CA on mRNA related to fatty acid uptake in high-fat diet feeding.
[0032] Fig.14 is the effect of CA on the protein levels of CD36, FATP1, and FABP1 in the liver of high-fat diet-fed mice.
[0033] Fig.15 The immunofluorescence results of the effects of CA on CD36, FATP1, and FABP1 proteins in the liver of mice fed a high-fat diet.
[0034] Fig.16 The effect of CA on the lipid secretion function of the liver fed with a high-fat diet.
[0035] Fig.17 is the effect of CA on plasma lipid levels in response to high-fat diet feeding.
[0036] Fig.18 is the effect of CA on small intestinal fatty acid uptake by protein in animals fed a high-fat diet. DETAILED DESCRIPTION
[0037] The specific implementation of the present disclosure is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described herein is only used to illustrate and explain the present disclosure, and is not used to limit the present disclosure.
[0038] A first aspect of the present disclosure provides a use of carnosic acid as a peroxisome proliferator-activated receptor antagonist.
[0039] According to the present disclosure, the structural formula of carnosic acid is shown in formula (1):
[0040]
[0041] In the presence of antagonist ligands, the fusion protein (SA-SRC1) containing the steroid receptor coactivator (SRC1) and the fusion protein (GST-NCOR2) containing the nuclear receptor corepressor (NCOR2) respectively produce different degrees of binding and dissociation with PPARγ, and SA-SRC1 produces binding with PPARγ / α, and the binding or dissociation level can reflect the antagonistic ability of PPARγ and / or PPARα with the ligand molecule. The inventors of the present disclosure have found that carnosic acid (CA) can promote the dissociation of PPARγ and SA-SRC1, inhibit the dissociation of PPARγ and GST-NCOR2, and promote the dissociation of PPARα and SA-SRC1, and CA has an inhibitory effect on the transcriptional activity of PPARγ and PPARα. Therefore, it can be seen that CA can be used as an antagonist of peroxisome proliferator-activated receptors, especially as an antagonist of PPARα subtype and / or PPARγ subtype of peroxisome proliferator-activated receptors.
[0042] A second aspect of the present disclosure provides use of carnosic acid in the preparation of a medicament for treating or improving metabolism-related fatty liver disease.
[0043] The inventors of the present disclosure have found in their studies that carnosic acid can act as an antagonist of the PPARα subtype and / or PPARγ subtype of peroxisome proliferator-activated receptor, which further has a therapeutic and / or improving effect on metabolism-related fatty liver disease.
[0044] According to the present disclosure, the drug treats or improves metabolic-related fatty liver disease by at least one of the following methods:
[0045] (1) Inhibit the transcription of peroxisome proliferator-activated receptors;
[0046] (2) inhibiting the expression of genes related to fatty acid uptake in liver cells;
[0047] (3) inhibiting the expression of fatty acid uptake-related proteins in liver cells and / or small intestinal cells;
[0048] (4) Promote the secretion of triglycerides in liver cells.
[0049] According to the present disclosure, the peroxisome proliferator-activated receptor is a PPARα subtype and / or a PPARγ subtype of a peroxisome proliferator-activated receptor;
[0050] The fatty acid uptake-related gene is one or more of FATP1, FABP1, FABP3 and CD36;
[0051] The fatty acid uptake-related protein is selected from one or more of FATP1, FABP1 and CD36.
[0052] The inventors of the present disclosure have found in their research that carnosic acid can be transcribed through the PPARα subtype and / or PPARγ subtype of peroxisome proliferator-activated receptors. It can inhibit the binding of peroxisome proliferator-activated receptors to steroid receptor coactivators, and / or inhibit the dissociation of peroxisome proliferator-activated receptors from nuclear receptor corepressors; specifically, inhibit the binding of peroxisome proliferator-activated receptors to SA-SRC1, and / or inhibit the dissociation of peroxisome proliferator-activated receptors from GST-NCOR1. It also inhibits the expression of fatty acid uptake-related genes (FATP1, FABP1, FABP3, CD36) in liver cells and / or small intestinal cells, inhibits the expression of fatty acid-related proteins CD36 and FATP1 in liver cells, promotes the secretion of triglycerides in liver cells, and inhibits the expression of fatty acid uptake-related proteins CD36 and FABP1 in small intestinal cells, thereby achieving the effect of treating and / or improving metabolism-related fatty liver disease.
[0053] According to the present disclosure, the metabolic-related fatty liver disease is based on fatty liver disease and is accompanied by at least one selected from obesity, type 2 diabetes and metabolic dysfunction. Specifically, the metabolic dysfunction is selected from at least two abnormal metabolic risk factors selected from central obesity, hypertension, hyperlipidemia, prediabetes and insulin resistance.
[0054] In a specific embodiment of the present disclosure, the metabolism-related fatty liver disease is fatty liver disease accompanied by prediabetes.
[0055] According to the present disclosure, the drug further comprises a pharmaceutically acceptable excipient. Wherein, the pharmaceutically acceptable excipient is selected from one or more of an excipient, a filler, a binder, a diluent and a disintegrant. In the present disclosure, the excipient, the filler, the binder, the diluent and the disintegrant can be selected from materials conventionally used by those skilled in the art, and will not be described in detail herein.
[0056] In the present disclosure, there is no specific limitation on the dosage form of the drug, and it may be, for example, injection, oral agent, patch, spray, pill, powder, ointment, pill, granule, capsule and tablet.
[0057] The present disclosure is further illustrated below by way of examples, but the present disclosure is not limited thereby.
[0058] Unless otherwise specified, the raw materials, reagents, instruments and equipment involved in the embodiments of the present disclosure can be obtained by purchase.
[0059] The experimental materials used in the embodiments of the present disclosure are shown in Table 1.
[0060] Table 1
[0061]
[0062] Statistical analysis:
[0063] GraphPad Prism 8.0.1 software was used to analyze the results. All experimental data are presented as mean ± standard deviation. The two groups were analyzed and compared by one-way ANOVA test, and non-parametric test was performed for non-normally distributed data. When P < 0.05, the difference between the groups was statistically significant.
[0064] In the drawings, “*” represents p<0.05, “**” represents p<0.01, “***” represents p<0.001, and “****” represents p<0.0001.
[0065] Example 1
[0066] This example is used to illustrate the analysis of the affinity between CA and PPARγ.
[0067] Surface plasmon resonance (SPR) was used to measure the affinity of CA to PPARγ:
[0068] CA was diluted with running buffer to 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.5625 μM and 0.78 μM, vortexed and mixed, sonicated for 5 min, centrifuged at 2000 rpm for 2 min, the supernatant was taken, the sample was placed in the sample rack, the "Screen" program of the Biacore control software was run, and the CA dilutions were injected from low concentration to high concentration in sequence. After the end, the Biacore T200 (purchased from GE, USA) analysis control software was used to analyze the binding of CA to PPARγ on the chip surface. The results are shown in Figure 2. Figure 1 shown. Figure 1 In the figure, the right figure shows the affinity relationship fitting diagram of the binding of different concentrations of carnosic acid to PPARγ, and the left figure shows the sensor line diagram of the binding of different concentrations of carnosic acid to PPARγ.
[0069] Depend on Figure 1 It can be seen that CA has a strong affinity for PPARγ, with an affinity value as high as KD = 6.57 × 10 -8 .
[0070] Example 2
[0071] This example is used to illustrate the effect of CA on the binding of PPARγ to a fusion protein (SA-SRC1) containing a steroid receptor coactivator (SRC1) and a fusion protein (GST-NCOR2) containing a nuclear receptor corepressor (NCOR2).
[0072] Streptavidin (SA) peptide (SA-SRC1) was prepared by mixing streptavidin and biotinylated SRC1 peptide at a molar ratio of 1:4. The pGEX-6p-1-GST-NCOR2 plasmid was transformed into Escherichia coli and amplified to induce the expression of GST fusion protein. The bacteria were collected, the cells were broken and centrifuged (4°C, 15000×g, 10min) to obtain the protein-containing supernatant. The target protein was purified by affinity chromatography and AKTA avant to isolate the peptide GST-NCOR2.
[0073] In the presence of agonist / antagonist ligands, steroid receptor coactivators and nuclear receptor corepressors bind and dissociate to different degrees with PPARγ, and their binding and dissociation levels can reflect the agonist / antagonist ability of PPARγ ligand molecules. Among them, full agonists such as rosiglitazone can lead to the maximum binding of PPARγ to SA-SRC1 or dissociation from GST-NCOR2.
[0074] The step-by-step injection method was used to exclude protein-small molecule / protein-protein interactions, and the PPARγ ligand properties of natural compounds were further analyzed by indirectly detecting the binding level of PPARγ protein with SA-SRC1 / GST-NCOR2. Figure 2 As shown, Figure 2 In the figure, the right figure shows that carnosic acid can inhibit the binding of PPARγ to SA-SRC1, and the left figure shows that carnosic acid can inhibit the dissociation of PPARγ from GST-NCOR2. GW9662, as a PPARγ / α dual antagonist, can inhibit the binding of PPARγ to SA-SRC1 to a certain extent in this experiment, and inhibit the dissociation of PPARγ from GST-NCOR2. Figure 2 As shown in the right figure, CA promoted the dissociation of PPARγ from SA-SRC1 and inhibited the dissociation of PPARγ from GST-NCOR2 to a greater extent than GW9662. This result indicates that CA may be an antagonist of PPARγ.
[0075] Example 3
[0076] This example is used to illustrate the effect of CA on the binding of PPARα to steroid receptor coactivator (SA-SRC1).
[0077] The PPARα ligand properties of natural compounds were further analyzed by indirectly detecting the binding level of PPARα protein to SA-SRC1. Figure 3 As shown, both CA and GW9662 promoted the dissociation of PPARα from SA-SRC1. This result suggests that CA may be an antagonist of PPARα.
[0078] Example 4
[0079] This example is used to illustrate the effects of CA and GW9662 on PPARγ transcriptional activity.
[0080] Experimental method: T293 cell suspension was inoculated in a 6-well plate. When the cells reached 50% confluence, PPRE-Luc and PPARγ / α were transfected using lipo2000 reagent (Thermo Fisher). Fresh culture medium was replaced after 6 hours. After 24 hours, the cells were digested and inoculated in a 96-well plate. After the cells adhered, different concentrations of carnosic acid (20, 10, 5, 2.5, 1.25, 0.625, 0.3125, 0) were used for intervention for 24 hours. The supernatant was added with coelenterazine and mixed. The luciferase activity was detected using a small animal imaging analyzer.
[0081] The results are as follows Figure 4 As shown in Figure 2, as the concentration increases, CA has an inhibitory effect on the transcriptional activity of PPARγ and PPARα, and the inhibitory effect is concentration-dependent ( Figure 4 A). GW9662 produces similar transcriptional inhibitory effects on PPARγ and PPARα transcriptional activities ( Figure 4 B), and the inhibitory effect was concentration-dependent.
[0082] Based on the results of Examples 1-4, it was inferred that CA might be a PPARα / γ dual antagonist.
[0083] Example 5
[0084] This example is used to illustrate the effect of CA on mice with metabolic-related fatty liver induced by a high-fat diet.
[0085] Experimental method: Method for establishing animal model of fatty liver induced by high-fat diet:
[0086] SPF 8-week-old male C57BL / 6n mice weighed 20±1g. After adaptive feeding, the mice were randomly divided into 4 groups according to body weight: ① control group (Chow group), fed with a normal diet (Xiaoshuyoutai, D12450j) with a fat energy supply ratio of 10Kcal%; ② model group (Nafld group), fed with a high-fat diet (Xiaoshuyoutai, D12492) with a fat energy supply ratio of 60Kcal%; ③ positive drug group (GW9662 group), fed with a high-fat diet, GW9662 (100μg / mL) was injected intraperitoneally three times a week; ④ Chinese medicine monomer group (CA group), fed with a high-fat diet containing 0.02% (W / W) CA. Except for the mice in the GW9662 group, the solvent was injected intraperitoneally to eliminate the influence of experimental operation. The animals were illuminated in half cycles of day and night, and the temperature (23-25℃) and humidity (49-51%) were constant. The experimental period was 12 weeks, and the body weight and food intake were recorded weekly during the experiment. All mice were purchased from Beijing Weitonglihua Animal Experiment Technology Co., Ltd., production license number: SCXK (Beijing) 2021-0006. All animal experiments were reviewed and filed by the Party Ethics Committee of the China Academy of Chinese Medical Sciences (ethics review approval number: ERCCACMS21-2306-01).
[0087] Related indicator detection methods:
[0088] (1) Ultrasound detection of liver and kidney in small animals:
[0089] After 12 hours of high-fat diet feeding, all mice were fasted for 8-12 hours and small animal liver ultrasound examination was performed. From the xiphoid cartilage to the kidney, 1 cm to the left of the midline of the mouse's axilla, 4 plane images were cut off on average. After each shot, a cross-section was taken at a fixed distance downward. The probe frequency was 30 Hz. The images were cut away from blood vessels, bile ducts or other image areas with uneven density. In the ultrasound influence map of the liver cross section, a section of about 0.3 mm was selected along the direction of ultrasound propagation. 2 There are two circular grayscale collection areas, and the distance between the two centers is about 1.7mm. The calculation formula of the echo attenuation coefficient is: a=(InAn-InAf) / (L*F). Among them, An and Af are the average grayscale values of images collected at different depths at the near wave source and far wave source ends along the propagation direction of the ultrasonic wave, L is the distance between the centers of the two circular grayscale collection areas, and F is the probe frequency. Liver-kidney index rate=average grayscale of the liver / average grayscale of the kidney.
[0090] (2) Organ index: liver-to-body ratio.
[0091] After 12 hours of high-fat diet feeding, mice were fasted for 8-12 hours and their body weights were recorded. The complete livers of all mice were removed, photographed and weighed. The liver organ index was calculated as liver weight / body weight × 100%.
[0092] (3) H&E staining of liver.
[0093] Mouse liver was collected and fixed in 4% paraformaldehyde for 48 hours before being trimmed. The tissue blocks were dehydrated, transparent, wax-impregnated, embedded, and sliced before being stained with H&E. Finally, the sections were sealed and dried, and then observed and photographed under an optical microscope (400×).
[0094] (4) Oil red O staining of liver.
[0095] Mouse liver was fixed with OCT embedding medium and then quickly frozen on dry ice. The slices were sliced and displayed using a fully automatic cryostat. The liver tissue slices were stained with oil red dye for lipid droplets, then stained with hematoxylin for nuclei, and finally sealed with glycerol-based aqueous mounting medium and dried. They were observed and photographed using an optical microscope (400×).
[0096] (5) Detection of total triglyceride and total cholesterol content in liver tissue:
[0097] Precooled 5% Triton-X100 was added to the liver tissue at a weight ratio of 1:10, and the tissue was homogenized at 65 Hz for 30 s, repeated 5 times, and centrifuged at 10,000 rpm for 10 min. The supernatant was collected and the protein content was detected using a BCA total protein quantification kit.
[0098] The supernatant was slowly heated from room temperature to 90°C in a water bath, and then heated at 90°C for 5 minutes. Cooled at room temperature for 30 minutes, and the above heating and cooling steps were repeated, followed by centrifugation, centrifuged at 4°C for 12,000 g for 5 minutes, and the supernatant was collected. The supernatant was collected to detect the triglyceride and total cholesterol content.
[0099] (6) Detection of liver damage indicators:
[0100] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) kits were used to detect plasma ALT and AST levels to evaluate the degree of hepatocyte damage.
[0101] (7) Oral glucose tolerance test:
[0102] All mice were placed in clean cages, fasted for 8 hours, and their blood sugar levels were measured after 8 hours of starvation. The mice were weighed. Glucose solution (2 g / kg body weight) was orally administered to the mice, and the timing was started after the administration. Blood sugar levels were measured and recorded at 15, 30, 60, and 120 minutes after the administration.
[0103] (8) Hunger and refeeding blood sugar test:
[0104] The blood sugar levels of all mice were recorded at the end of the meal, and then they were placed in clean cages. The blood sugar levels were tested and recorded after fasting for 6 and 12 hours. The mice were then fed again, and the blood sugar levels were tested and recorded 2 hours after the meal.
[0105] Experimental results:
[0106] 1. Effects of CA on fatty liver and liver-to-body ratio induced by high-fat diet:
[0107] like Figure 5 As shown in the figure, the liver of mice in the Chow group was reddish brown by macroscopic observation, while the liver of the Nafld group was yellow by macroscopic observation compared with the Chow group; compared with the Nafld group, the GW9662 group and the CA group were obviously ruddy in color, and the yellow was lighter. The results of the liver-to-body ratio showed that compared with the Chow group, the Nafld liver index increased; compared with the Nafld group, the liver index of the GW9662 and CA groups decreased. The results showed that the Nafld group mice had lipotoxic damage when fed a high-fat diet for 12 weeks, while the lipotoxic damage of the liver of Nafld mice was reduced under the intervention of GW9662 and CA.
[0108] 2. Effect of CA on the ultrasonic attenuation coefficient of liver induced by high-fat diet:
[0109] like Figure 6 As shown in the figure, according to the results of liver small animal ultrasound, the Chow group showed low to medium echoes. Compared with the Chow group, the liver echoes were enhanced and dense, the spots were enhanced, and the dense and small dot-like echoes were diffusely distributed; compared with the Nafld group, the high-density echoes in the GW9662 group and the CA group were weakened ( Figure 6 C). The near-field echo of the liver is brightly enhanced, while the far-field echo is attenuated. The more severe the fatty degeneration of the liver, the more obvious the far-field attenuation of the liver. The liver attenuation coefficient is a more accurate method to evaluate the degree of fatty liver. Figure 6 Results of A and 6B showed that compared with the Chow group, the far-field echo of the liver in the Nafld group was significantly attenuated; compared with the Nafld group, the far-field echo attenuation of the GW9662 group and the CA group was reduced. Ultrasound results showed that the Nafld group had severe fatty degeneration, and GW9662 and CA could significantly improve fatty degeneration of the liver.
[0110] 3. Effect of CA on ultrasonic liver and kidney index rate induced by high-fat diet:
[0111] like Figure 7 As shown in the figure, according to the ultrasound results of small animals with liver and kidney in the same field of view, the liver and kidney index ratio was determined by collecting the average grayscale of the selected areas of liver and kidney. The liver and kidney echo index ratio of the Chow group was <1:1; the liver and kidney echo index of the Nafld group was >1:1, which was much higher than that of the Chow group; compared with the Nafld group, the liver and kidney echo ratio of the GW9662 group and the CA group was reduced ( Figure 7 A and 7B).
[0112] 4. Effects of CA on hepatocyte damage in fatty liver fed with high-fat diet:
[0113] like Figure 8 As shown in the results of ALT and AST content, compared with the Chow group, the plasma ALT content of mice in the Nafld group was significantly increased; compared with the Nafld group, the plasma ALT content of mice in the GW9662 group and the CA group was significantly decreased ( Figure 8 B). There was no significant difference in AST content between the groups ( Figure 8 A). The results showed that mice fed a long-term high-fat diet had hepatocellular damage, and GW9662 and CA intervention improved the hepatocellular damage induced by the high-fat diet.
[0114] HE staining results showed that the hepatocytes and hepatic lobules of mice in the Chow group were intact, and the liver tissue structure was clearly arranged. Compared with the Chow group, large and dense vacuoles appeared in the liver of mice in the Nafld group, with a small number of non-fatty cells remaining and disordered liver structure. Compared with the Nafld group, the vacuoles in the liver of mice in the GW9662 group and the CA group were greatly reduced, and the number of non-fatty cells increased ( Figure 8 C).
[0115] 5. Effects of CA on hepatic lipid deposition induced by high-fat diet:
[0116] like Fig. 9 As shown, according to the results of liver oil red staining ( Fig. 9 C). Compared with the control group, the Nafld group had severe lipid deposition in the liver; compared with the Nafld group, the lipid deposition in the GW9662 group and the CA group was reduced. Long-term high-fat diet feeding can lead to hepatic steatosis. GW9662 and CA intervention can improve hepatic steatosis induced by high-fat diet feeding. According to the results of triglyceride (TG) and total cholesterol (TC) content in the liver, ( Fig. 9 A and 9B), compared with the control group, the TG and TC levels in the liver of the Nafld group increased; compared with the Nalfd group, the TG level in the liver of the GW9662 group decreased, and the TC level increased; compared with the Nafld group, the TG level in the CA group decreased, and the TC level remained unchanged. GW9662 alleviated the problem of hepatic triglyceride deposition caused by a high-fat diet, while increasing the cholesterol level in the liver; while CA reduced the triglyceride level in the liver, and did not increase the cholesterol level in the liver.
[0117] 6. Effects of CA on body weight and food intake induced by high-fat diet:
[0118] The results of the 12-week weight change analysis showed that ( Fig.10), compared with the Chow group, the Nafld group had the largest final weight and faster weight gain; compared with the Nafld group, the GW9662 group and the CA group had lower final weight and slower weight gain. Long-term high-fat diet intake will lead to weight gain, and GW9662 and CA intervention will alleviate the problem of excessive weight gain caused by a high-fat diet.
[0119] The results of food intake over 12 weeks showed that the food intake of the Chow group was higher than that of the high-fat diet groups (Nafld, GW9662, and CA groups). The intake of mice on the high-fat, high-calorie diet was significantly lower than that on the normal control diet.
[0120] 7. Effect of CA on glucose metabolism induced by high-fat diet:
[0121] The results of fasting blood glucose analysis showed that ( Fig.11 C), compared with the control group, the fasting blood glucose in the Nafld group increased; compared with the Nafld group, the fasting blood glucose in the GW9662 group decreased, and the fasting blood glucose in the CA group decreased, but it was not statistically significant (p = 0.08). Long-term high-fat diet feeding can lead to impaired fasting blood glucose, and GW9662 and CA intervention can improve the impaired fasting blood glucose caused by high-fat diet feeding.
[0122] According to the results of oral glucose tolerance test (OGTT), Fig.11 A and 11B), compared with the control group, after oral glucose administration, the blood glucose levels of the Nafld group increased at 15, 30, 60, and 120 min, and the area under the curve increased significantly; compared with the Nafld group, there was no difference in blood glucose levels at different time points in the GW9662 group, and the blood glucose level at 15 min in the CA group decreased, and there was no significant difference in the area under the curve. Long-term high-fat diet feeding can lead to impaired glucose tolerance, and GW9662 and CA intervention can improve impaired glucose tolerance caused by reformed diet feeding.
[0123] After fasting, the body synthesizes excess glucose into glycogen for storage; when hungry, the body uses the stored glutinous rice balls to break down glycogen into glucose. According to the analysis of random blood sugar and 6h blood sugar results after starvation, ( Fig.11 D), compared with the Chow group, the random blood glucose of the Nafld group was significantly increased; compared with the Nafld group, the random blood glucose of the GW9662 group remained unchanged, and the random blood glucose of the CA group was significantly decreased (p < 0.05); there was no significant difference in the blood glucose consumed by all groups after 6 hours of fasting.
[0124] The results of blood glucose analysis after fasting for 12 hours and refeeding for 2 hours showed that ( Fig.11F), there was no significant difference in blood glucose after fasting for 12 hours in all groups; compared with the Chow group, blood glucose in the Nafld group increased significantly after refeeding for 2 hours; compared with the Nafld group, blood glucose in the GW9662 group and the CA group decreased after refeeding for 2 hours, but it was not statistically significant.
[0125] Example 6
[0126] This example is used to illustrate the effect of CA on the lipid metabolism function of the liver in fatty liver induced by high-fat diet.
[0127] Experimental methods:
[0128] (1) Mouse liver fatty acid uptake experiment:
[0129] The mice were weighed after starvation for 6 hours, and blood was collected from the eye sockets and recorded as the initial point. The mice were intraperitoneally injected with Bodipy-C16 (0.5 μg / g body weight), and blood was collected from the eye sockets 1, 3, and 5 hours after the injection. The mice were killed after blood was collected at the 5-hour time point, and the liver was collected. The liver was lysed with Ripa, and the tissue was homogenized and centrifuged to obtain the supernatant. The fluorescence in the plasma and liver tissue lysate was detected (excitation light 485 nm, emission light 515 nm).
[0130] (2) Mouse liver lipid secretion experiment:
[0131] All mice were starved for 6 hours and weighed, and blood was collected from the eye sockets and recorded as the initial point. P407 (0.5 mg / g body weight) was injected intraperitoneally into the mice, and blood was collected from the eye sockets 1, 3, and 5 hours after injection. The final plasma triglyceride and total cholesterol levels were measured at each time point.
[0132] (3) Detection of liver mRNA levels:
[0133] After the liver tissue is homogenized with Trizol, it is centrifuged with chloroform to obtain the supernatant, mixed with isopropanol, and then centrifuged to retain the precipitate and discard the supernatant. The precipitate is washed twice with 75% ethanol, centrifuged and discarded the supernatant, and the precipitate is dried. According to the amount of precipitate, 50-100μLDEPC water is added to dissolve the precipitate. The RNA concentration is detected to make the RNA concentration between 300 and 800ng / μL and the A260 / A280 ratio between 1.95 and 2.05. The mRNA is reverse transcribed into cDNA using a reverse transcription kit, and then subjected to fluorescent quantitative PCR reaction and determination. The relative expression of the mRNA of the target gene is calculated and analyzed by the experimental results = 2 -ΔΔCT .
[0134] (4) Detection of plasma lipid content:
[0135] The final plasma triglyceride (TG), total cholesterol (TC), free fatty acid (FFA), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were detected using a blood biochemical detector.
[0136] (5) Detection of liver PPARγ protein content: Western Blot experiment.
[0137] Liver tissue was homogenized with RIPA lysis buffer and centrifuged to obtain the supernatant, and the total protein content was detected by BCA total protein quantification kit. The protein samples were electrophoresed, transferred to membrane, blocked, primary antibody, secondary antibody, washed, developed and image gray value analyzed.
[0138] (6) Detection of liver CD36, FATP1, and FABP1 protein content: Western Blot experiment.
[0139] Liver tissue was homogenized with RIPA lysis buffer and centrifuged to obtain the supernatant, and the total protein content was detected by BCA total protein quantification kit. The protein samples were electrophoresed, transferred to membrane, blocked, primary antibody, secondary antibody, washed, developed and image gray value analyzed.
[0140] (7) Liver CD36, FATP1, and FABP1 immunofluorescence experiments.
[0141] The liver tissue was fixed, dehydrated, embedded, sectioned, dewaxed, antigen repaired, blocked, primary and secondary antibodies were used, washed, and sealed with Dapi anti-quenching mounting medium. After 24 hours, laser confocal scanning was performed to take pictures and perform fluorescence quantitative analysis.
[0142] (8) Small intestine CD36 and FABP1 immunofluorescence experiment.
[0143] After fixation, the small intestinal tissue was dehydrated and embedded, and then sectioned and dewaxed, antigen repaired, blocked, primary and secondary antibodies were used, and then washed and sealed with Dapi mounting medium containing anti-quenching. After 24 hours, laser confocal scanning was performed to take pictures and perform fluorescence quantitative analysis.
[0144] Experimental results:
[0145] (1) Effects of CA on hepatic fatty acid uptake in mice with high-fat diet-induced fatty liver:
[0146] According to the results of the Bodipy-C16 fatty acid uptake experiment ( Fig.12AC), compared with the Chow group, the level of Bodipy-C16 absorbed from the peritoneal cavity into the plasma of mice in the Nafld group was increased; compared with the Nafld group, the level of Bodipy-C16 absorbed from the peritoneal cavity into the plasma of mice in the GW9662 and CA groups was decreased. Compared with the control diet, high-fat diet feeding led to increased fatty acid intake, and GW9662 and CA intervention could reduce the high fatty acid intake caused by the high-fat diet.
[0147] Compared with the Chow group, the Bodipy-C16 content in the liver of the mice in the Nafld group was increased; compared with the Nafld group, the Bodipy-C16 content in the liver of the mice in the GW9662 and CA groups was decreased ( Fig.12 D). Compared with the control diet, long-term high-fat diet feeding induced an increase in the liver fatty acid uptake capacity of mice, leading to the formation of fatty liver; GW9662 and CA intervention can reduce the high fat uptake in the liver caused by the high-fat diet, thereby improving the liver fat deposition induced by the high-fat diet.
[0148] (2) Effects of CA on hepatic fatty acid uptake genes in mice with high-fat diet-induced fatty liver:
[0149] like Fig.13 As shown, according to the qPCR results, compared with the Chow group, the mRNA levels of FABP1, FABP3, and FATP1 in the Nafld group were increased; compared with the Nafld group, the mRNA levels of FATP1 and FABP3 in the GW9662 group were decreased, and the mRNA levels of FABP3 and FATP1 in the CA group mice were decreased. Long-term high-fat diet-induced fatty liver mice will lead to an increase in genes related to liver fatty acid uptake, which in turn leads to an increase in the fatty acid uptake capacity of the liver in fatty liver mice. GW9662 and CA intervention led to a decrease in genes related to liver fatty acid uptake, thereby improving the impaired fatty acid uptake capacity of the liver in fatty liver mice.
[0150] (3) Effects of CA on hepatic fatty acid uptake protein in mice with high-fat diet-induced fatty liver:
[0151] like Fig.14 As shown, according to the Western blot results, compared with those in the Chow group, the protein levels of CD36, FABP1 and FATP1 in the Nafld group were increased; compared with those in the Nafld group, the protein levels of CD36, FABP1 and FATP1 in the GW9662 group were decreased, and the protein levels of FABP1 and FATP1 in the CA group mice were decreased.
[0152] like Fig.15As shown, according to the immunofluorescence results, the protein levels of CD36, FABP1, and FATP1 in the Nafld group were increased compared with the Chow group; the protein levels of CD36 and FABP1 in the GW9662 group were decreased compared with the Nafld group; and the protein levels of CD36 and FATP1 in the CA group mice were decreased compared with the Nafld group.
[0153] Long-term high-fat diet-induced fatty liver in mice leads to an increase in liver fatty acid uptake-related proteins, which in turn leads to an increase in the liver fatty acid uptake capacity of fatty liver mice. GW9662 and CA intervention leads to a decrease in liver fatty acid uptake-related proteins, which in turn improves the impaired liver fatty acid uptake capacity of fatty liver mice.
[0154] (4) Effects of CA on hepatic lipid secretion in mice with high-fat diet-induced fatty liver:
[0155] like Fig.16 As shown in the results of liver lipid secretion, compared with the Chow group, after intraperitoneal injection of P407, the level of hepatic triglyceride secretion into the blood of mice in the Nafld group was reduced; compared with the Nafld group, the level of hepatic triglyceride secretion into the blood of mice in the GW9662 group and the CA group was increased. Long-term high-fat diet feeding leads to decreased hepatic lipid secretion function, liver lipid accumulation, and then fatty liver; GW9662 and CA intervention improve the impaired hepatic lipid secretion function and liver lipid deposition caused by high-fat diet feeding, thereby protecting the liver from lipotoxic damage.
[0156] According to the qPCR results, compared with that in the Chow group, the mRNA level of Mttp in the liver of mice in the Nafld group was decreased, thereby reducing the triglyceride secretion function of the liver; compared with that in the Nafld group, the mRNA level of Mttp in the GW9662 and CA groups remained unchanged.
[0157] (5) Effects of CA on plasma lipid levels in mice with high-fat diet-induced fatty liver:
[0158] like Fig.17 As shown in the figure, according to the blood biochemical results, compared with the Chow group, the TG and FFA levels of the mice in the Nafld group were decreased; compared with the Nafld group, the TG levels of the mice in the GW9662 and CA groups remained unchanged and the FFA levels were decreased. Compared with the Chow group, the TC level of the mice in the Nafld group increased, and the LDL-C and HDL-C levels remained unchanged; compared with the Nafld group, the TC level of the mice in the GW9662 and CA groups increased, among which the LDL-C level of the mice in the GW9662 group increased, and the LDL-C and HDL-C levels of the mice in the CA group increased.
[0159] (3) Effects of CA on small intestinal fatty acid uptake protein in mice with high-fat diet-induced fatty liver:
[0160] like Fig.18 As shown, according to the immunofluorescence results, the protein levels of CD36 and FABP1 in the Nafld group were increased compared with the Chow group; compared with the Nafld group, the protein expression of CD36 and FABP1 in the GW9662 group was decreased, and the protein levels of CD36 and FABP1 in the CA group mice were decreased. Long-term high-fat diet-induced fatty liver mice will lead to an increase in liver fatty acid uptake-related proteins, which in turn leads to an increase in the liver fatty acid uptake capacity of fatty liver mice. GW9662 and CA intervention led to a decrease in liver fatty acid uptake-related proteins, thereby improving the impaired liver fatty acid uptake capacity of fatty liver mice.
[0161] The preferred embodiments of the present disclosure are described in detail above in conjunction with the accompanying drawings; however, the present disclosure is not limited to the specific details in the above embodiments. Within the technical concept of the present disclosure, a variety of simple modifications can be made to the technical solution of the present disclosure, and these simple modifications all fall within the protection scope of the present disclosure.
[0162] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.
[0163] In addition, various embodiments of the present disclosure may be arbitrarily combined, and as long as they do not violate the concept of the present disclosure, they should also be regarded as the contents disclosed by the present disclosure.
Claims
1. Application of carnosic acid as a peroxisome proliferator-activated receptor antagonist.
2. The use according to claim 1, wherein: The carnosic acid acts as an antagonist of the PPARα subtype and / or the PPARγ subtype of the peroxisome proliferator-activated receptor.
3. Use of carnosic acid in the preparation of drugs for treating or improving metabolism-related fatty liver disease.
4. The use according to claim 3, wherein: The drug treats or improves metabolic-related fatty liver disease by at least one of the following methods: (1) Inhibit the transcription of peroxisome proliferator-activated receptors; (2) inhibiting the expression of genes related to fatty acid uptake in liver cells; (3) inhibiting the expression of fatty acid uptake-related proteins in liver cells and / or small intestinal cells; (4) Promote the secretion of triglycerides in liver cells.
5. The use according to claim 4, wherein: The peroxisome proliferator-activated receptor is a PPARα subtype and / or a PPARγ subtype of a peroxisome proliferator-activated receptor; The fatty acid uptake-related gene is selected from one or more of FATP1, FABP1, FABP3 and CD36; The fatty acid uptake-related protein is selected from one or more of FATP1, FABP1 and CD36.
6. The use according to claim 4, wherein: The metabolism-related fatty liver disease is based on fatty liver disease and is accompanied by at least one selected from obesity, type 2 diabetes and metabolic dysfunction.
7. The use according to claim 6, wherein: The metabolic dysfunction is selected from abnormalities in at least two metabolic risk factors among central obesity, hypertension, hyperlipidemia, prediabetes and insulin resistance.
8. The use according to claim 7, wherein: The metabolism-related fatty liver disease is based on fatty liver disease accompanied by prediabetes.
9. The use according to claim 3, wherein: The drug also includes pharmaceutically acceptable excipients.
10. The use according to claim 9, wherein: The pharmaceutically acceptable excipient is selected from one or more of an excipient, a filler, a binder, a diluent and a disintegrant.
Citation Information
Patent Citations
Medical use of carnosic acid
WO2016145982A1
